Cytokinetics CYTK
NASDAQ CYTK
$72.72 -1.23 (-1.66%)
As of: Sep 4, 2026 · 3:59 PM EDT

Cytokinetics (CYTK) Gross Profit (2025 - 2026)

Cytokinetics (CYTK) posted quarterly Gross Profit of $19.2 million for Q1 2026, up 1115.64% year-over-year from $1.6 million in Q1 2025, and up 1115.64% quarter-over-quarter from $1.6 million in Q1 2025.

Analysis

Cytokinetics (CYTK) Gross Profit (2025 - 2026) Analysis & Trends

Cytokinetics (CYTK) has reported Gross Profit for 2 consecutive years, with $19.2 million the latest figure, recorded in Q1 2026.

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Vertex Pharmaceuticals 138.47 Bn 130.62 Bn 2.84 Bn
2 Regeneron Pharmaceuticals 85.18 Bn 77.19 Bn 3.93 Bn
3 Argenx Se 63.38 Bn 58.19 Bn 1.37 Bn
4 Moderna 58.09 Bn 52.95 Bn 52.00 Mn
5 Revolution Medicines 44.33 Bn 44.33 Bn -
6 BeOne Medicines 40.02 Bn 34.92 Bn 1.53 Bn
7 Alnylam Pharmaceuticals 35.57 Bn 32.27 Bn 992.69 Mn
8 Royalty Pharma 28.45 Bn 27.61 Bn -
9 Insmed 27.48 Bn 26.32 Bn 358.27 Mn
10 Cytokinetics 9.63 Bn 8.46 Bn 25.89 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 25.89 Mn
Mar 31, 2026 19.20 Mn
Jun 30, 2025 66.77 Mn
Mar 31, 2025 1.58 Mn